00:48 , Feb 1, 2019 |  BC Week In Review  |  Company News

Pfizer launches China's first pay-for-performance model for cancer

Pfizer Inc. (NYSE:PFE) launched a pay-for-performance insurance program for its breast cancer drug Ibrance palbociclib in China on Jan 23. The program is the nation's first pay-for-performance insurance for oncology and covers 34 Chinese cities,...
22:16 , Jan 25, 2019 |  BC Extra  |  Company News

Pfizer launches China's first pay-for-performance model for cancer

Pfizer Inc. (NYSE:PFE) launched a pay-for-performance insurance program for its breast cancer drug Ibrance palbociclib in China. The program is the nation's first pay-for-performance insurance for oncology and covers 34 Chinese cities, according to state-run...
01:05 , Jan 4, 2019 |  BC Week In Review  |  Company News

Xynomic returns to Boehringer for second cancer candidate

Xynomic Pharmaceuticals (Dover, Del.) gained exclusive, worldwide rights to BI 860585 from Boehringer Ingelheim GmbH (Ingelheim, Germany). Response from Xynomic Business Development Manager Angela Fung told BioCentury that Xynomic will pay Boehringer up to $800...
19:50 , Nov 2, 2018 |  BC Week In Review  |  Clinical News

Syndax's entinostat misses PFS endpoint in Phase III for breast cancer

Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) reported that entinostat (SNDX-275) missed the primary endpoint of improving progression-free survival (PFS) in the Phase III E2112 trial to treat breast cancer. The company said the trial will continue as...
17:37 , Oct 26, 2018 |  BC Extra  |  Clinical News

Syndax slides on entinostat PFS miss in breast cancer

Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) fell $1.03 (17%) to $5.01 Friday after reporting late Thursday that entinostat missed the primary endpoint of improving progression-free survival in the Phase III E2112 trial to treat breast cancer. The...
16:57 , Oct 26, 2018 |  BC Week In Review  |  Company News

NICE recommends against abemaciclib for untreated breast cancer

The U.K.'s NICE issued draft guidance recommending against the use of Verzenio abemaciclib from Eli Lilly and Co. (NYSE:LLY) in combination with an aromatase inhibitor for untreated advanced hormone-receptor positive, HER2-negative breast cancer. NICE said...
02:58 , Sep 1, 2018 |  BioCentury  |  Politics, Policy & Law

Stepping Through

Once considered obstacles to biomedical product development, regulators around the world have become enablers of the kinds of scientific and economic innovations that will underpin new business models. They are building gateways that could help...
18:56 , Aug 31, 2018 |  BC Week In Review  |  Clinical News

Novartis' PI3Kα inhibitor meets in Phase III for breast cancer

Novartis AG (NYSE:NVS; SIX:NOVN) said alpelisib (BYL719) met the primary endpoint in the Phase III SOLAR-1 trial to treat advanced breast cancer in previously treated patients that harbor the phosphoinositide 3-kinase (PI3K) catalytic subunit α...
21:36 , Aug 23, 2018 |  BC Extra  |  Clinical News

Novartis' PI3Kα inhibitor meets in Phase III for breast cancer

Novartis AG (NYSE:NVS; SIX:NOVN) said alpelisib (BYL719) met the primary endpoint in the Phase III SOLAR-1 trial to treat advanced breast cancer in previously treated patients that harbor the phosphoinositide 3-kinase (PI3K) catalytic subunit α...
20:49 , Jul 18, 2018 |  BC Extra  |  Company News

FDA real-time pilot speeds Kisqali label expansion

FDA announced on Wednesday that it approved Kisqali ribociclib from Novartis AG (NYSE:NVS; SIX:NOVN) in combination with an aromatase inhibitor for breast cancer in premenopausal and perimenopausal women in the first-line setting, five months ahead...